News Breaks |
|
|
| February 14, 2013 |
| 06:32 EDT |  | REGN | Regeneron reports Q4 EPS $1.47 ex-items, consensus $1.11
Reports Q4 revenue $414.6M, consensus $392.64M. Total revenues included EYLEA U.S. net product sales of $276M. |
|
|
News For REGN From The Last 14 Days Check below for free stories on REGN the last two weeks. |
|
|
| May 17, 2013 |
| 10:07 EDT |  | REGN | On The Fly: Analyst Initiation Summary
 Subscribe for More Information |
|
| 07:16 EDT | | REGN | Regeneron initiated with a Neutral at UBS
Subscribe for More Information |
|
| 06:33 EDT |  | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 15, 2013 |
| 05:39 EDT |  | REGN | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 14, 2013 |
| 07:34 EDT |  | REGN | Regeneron outlook positive, says RBC Capital
Subscribe for More Information |
|
| May 10, 2013 |
| 07:24 EDT | | REGN | Credit Suisse to host a conference
Subscribe for More Information |
|
| May 6, 2013 |
| 09:02 EDT | | REGN | Regeneron price target raised to $314 from $200 at Roth Capital
Subscribe for More Information |
|
|
|
|
|
